1 / 8

FDA s Current Considerations of Parvovirus B19 Nucleic Acid Testing NAT

FDA's Discussion of Parvovirus B19 NAT (I). Sep 1999 Blood Products Advisory Committee (BPAC)Safety of Pooled Plasma S/D Treated correlated with those lots having <104 geq/mL of B19 DNA in manufacturing pool (a phase 4 study). For plasma for further manufacturing, B19 NAT screening was recommende

elgin
Download Presentation

FDA s Current Considerations of Parvovirus B19 Nucleic Acid Testing NAT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related